Gene and Cell Therapy Drug FDA Approval

May 26, 2024
News

Breaking News! Pfizer Inc. has just received FDA approval for Beqvez™, a groundbreaking gene therapy for adults with moderate to severe hemophilia B. Beqvez offers a life-changing treatment option for those who currently use factor IX prophylaxis therapy or have experienced serious bleeding episodes and is currently priced at $3.5 million

At Symphony Benefits Solution, we understand the importance of innovative therapies like Beqvez. Our team specializes in helping payers and risk-bearing entities navigate the landscape of cutting-edge treatments while effectively containing costs. We offer tailored cost-containment solutions to optimize benefits and ensure access to transformative healthcare options. Contact us today to learn more about how Symphony Benefits Solution can support your organization in managing healthcare costs.

I’m not sure what I would have done without your help. You arranged for a second opinion at a hospital I didn’t even realize I could go to and they recommended a totally different treatment. I have no way to thank you for possibly saving my life.

49 y/o Survivor Diagnosed with Renal Cell Carcinoma

It is so nice to have someone fighting for me and helping me through all of this.

29 y/o Survivor Diagnosed with Ovarian Cancer

I am grateful to the dedicated team at Renalogic for their support and expertise throughout my journey. Their personalized approach to diet and exercise has been invaluable in helping me achieve and surpass my weight loss goals.

Member

We have been working with Interlink for over fifteen years utilizing their Transplant COE.  We greatly value their staff expertise, support, and flexibility.  Several of our self-funded clients are in a market that had historically directed transplants to facilities that were close geographically, but prohibitively expensive.  Interlink was able to provide concise and specific outcomes and cost data to illustrate that an alternative facility in a location just a little further away made much more sense.  Without the outcomes data, we could not have convinced members and providers to re-evaluate and re-direct to more cost effective facilities which provide transplant patients with documented better outcomes.  Interlink has been a strategic partner to us and our clients in this critical area of health plan management. 

Senior Vice President, Lockton Companies

Having this program and having a nurse reach out to check on me, see how I was doing, and if there's anything I needed or that they could do for me, has made a HUGE difference for me and I know it makes a difference for all the other patients that are lucky enough to have it.

56 y/o Survivor Diagnosed with Bladder Cancer

Renalogic and its cost containment methodology decreased that first dialysis claim to $120,000, and it didn’t even hit their Stop-Loss policy. It was a home run for everybody.

Broker-Partner

Get Updates And Stay Connected -Subscribe To Our Newsletter

Symphony Benefits Solution delivers comprehensive healthcare benefit platforms, specializing in transplant, cancer, ESRD, and gene & cell therapy, ensuring exceptional patient outcomes through cutting-edge care and expertise.

Gene and Cell Therapy Drug FDA Approval

Get Updates And Stay Connected -Subscribe To Our Newsletter

Contact Information

Recent News

Charting New Frontiers: The Impact of Gene and Cell Therapy on Healthcare

INTERLINK Premier Medical Round Table ‘Gene Therapy Has Arrived What Does the Future Hold’

Sickle Cell Gene Therapy Discussion